Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

>2 years 6-10 visits Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Investigational Medicines InjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Erbitux

Erbitux is a cancer treatment used to help slow the growth of certain colorectal and head and neck cancers.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cetuximab

Cetuximab is a substance that targets a protein on cancer cells to help slow or stop growth in colorectal and head and neck cancers.

Sodium Chloride

Sodium chloride is a substance used to replace salts and fluids in the body and to clean or irrigate wounds and nasal passages.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ficlatuzumab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur

Oncologie

Saint-Servais, Belgium

Vitaz

Oncologie

Sint-Niklaas, Belgium

CHU De Liege

Oncologie

Tilff, Belgium

Sponsor: Aveo Pharmaceuticals Inc.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.